Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial
Document type:
Meeting Abstract
Author(s):
Fasching, P. A.; Quek, R. G. W.; Bhattacharyya, H.; Hurvitz, S. A.; Rugo, H. S.; Ettl, J.